ArticleAnnals of translational medicine2022

A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma.

Yanyan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.